Kura Oncology KURA
NASDAQ KURA
$9.86 -0.02 (-0.20%)
At close: Oct 22, 2026 · 4:00 PM EDT

Kura Oncology (KURA) Net Margin (2025 - 2026)

Updated

Kura Oncology's Net Margin was -327.33% in Q2 2026, up 105.18 percentage points from -432.51% a year earlier and up 74.16 percentage points from the prior quarter.

Analysis

Kura Oncology (KURA) Net Margin (2025 - 2026) Analysis & Trends

On a trailing twelve-month basis, Kura Oncology's Net Margin was -384.30% through Jun 30, 2026; for FY2025, it was -412.95%, down 90.06 percentage points from FY2024.

  • In earlier years, Net Margin was -322.89% in FY2024.
  • Per Business Quant data, KURA's Net Margin in the three quarters before Q2 2026 was -401.49% (Q1 2026), -467.23% (Q4 2025) and -357.19% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn 0.83%
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn 21.27%
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -8.04%
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn 22.65%
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn 16.30%
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn 23.62%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -134.51%
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -1.65%
10 Kura Oncology 873.00 Mn -1.44 Bn 20.63 Mn -327.33%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -327.33%
Mar 31, 2026 -401.49%
Dec 31, 2025 -467.23%
Sep 30, 2025 -357.19%
Jun 30, 2025 -432.51%
Mar 31, 2025 -407.07%
API Access

Kura Oncology Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=KURA&period=max&api_key=YOUR_API_KEY